<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03811938</url>
  </required_header>
  <id_info>
    <org_study_id>IRAS 202816</org_study_id>
    <nct_id>NCT03811938</nct_id>
  </id_info>
  <brief_title>Ablation of Low Voltage Regions in Persistent Atrial Fibrillation</brief_title>
  <acronym>ABLOVO-AF</acronym>
  <official_title>Catheter ABlation of Low Voltage Regions in the Treatment of Persistent Atrial Fibrillation (ABLOVO-AF Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background. Atrial fibrillation (AF) is a disorganised rhythm of the upper chambers of the&#xD;
      heart. It can lead to severe complications including stroke or heart failure. It can be&#xD;
      treated with radiofrequency ablation (RFA). This technology works by heating heart muscle&#xD;
      inside the heart to break the electrical circuits responsible for the abnormal rhythm.&#xD;
&#xD;
      The energy is delivered into the heart with plastic tubes that have metal electrodes,&#xD;
      inserted through the groin veins and removed after the procedure. The patient is usually put&#xD;
      to sleep during the intervention.&#xD;
&#xD;
      If the AF has been present for more than seven days but for less than one year it is called&#xD;
      persistent, and it can be difficult to treat successfully with the usual methods.&#xD;
&#xD;
      Goals. The study will test a new RFA technique to treat patients with persistent AF. This&#xD;
      involves identifying areas within the left upper chamber that have a lower electrical voltage&#xD;
      than the surrounding heart muscle and applying RFA to the border zones of these areas.&#xD;
&#xD;
      Methods. The new technology combined with the usual procedure will be compared to the usual&#xD;
      procedure alone. All patients will receive ablation according to the new technique and&#xD;
      results will be compared to a historical control group from the trial institution.&#xD;
&#xD;
      Follow up. Patients will be followed up for 12 months with clinic visits and heart rhythm&#xD;
      checks.&#xD;
&#xD;
      Potential benefit. The new technique will be assessed for success at keeping patients free&#xD;
      from persistent AF compared to the usual methods.&#xD;
&#xD;
      The study will be performed at Imperial College Healthcare NHS Trust, at the Hammersmith&#xD;
      Hospital. Licensed clinical software will be used from St Jude Medical to guide ablation and&#xD;
      a special research software module will be used to analyse data from the heart following&#xD;
      ablation. The study will be sponsored by Imperial College Healthcare NHS Trust&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">August 24, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial fibrillation recurrence</measure>
    <time_frame>3-12 months.</time_frame>
    <description>Recurrence of atrial arrhythmia of at least 30s in duration. Investigation period for arrhythmia recurrence will be between 3 and 12 months after the first procedure, allowing for a blanking period of 3 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Canadian Cardiovascular Society Severity in Atrial Fibrillation Score</measure>
    <time_frame>12 months</time_frame>
    <description>Canadian Cardiovascular Society Severity in Atrial Fibrillation (CCS-SAF) change.&#xD;
0 represents no symptoms, 4 represents symptoms that significantly interfere with quality of life and exercise capacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiarrhythmic drugs</measure>
    <time_frame>3-12 months</time_frame>
    <description>Change in the number of antiarrhythmic drugs per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of AF ablations</measure>
    <time_frame>3-12 months</time_frame>
    <description>Number of additional AF ablations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rate</measure>
    <time_frame>3-12 months</time_frame>
    <description>Number and rate of complications in the study population.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Pulmonary Vein Isolation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Historical control from cases performed in year 2017 at Hammersmith Hospital. Intervention: Pulmonary vein isolation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low voltage ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active arm, Intervention: Standard pulmonary vein isolation and Low Voltage Ablation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Low voltage ablation</intervention_name>
    <description>Catheter ablation of low voltage areas in the left atrium and catheter ablation aiming for the electrical isolation of the pulmonary veins.</description>
    <arm_group_label>Low voltage ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary Vein Isolation</intervention_name>
    <description>Catheter ablation aiming for the electrical isolation of the pulmonary veins.</description>
    <arm_group_label>Pulmonary Vein Isolation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Suitable candidate for catheter mapping/ablation for arrhythmias.&#xD;
&#xD;
          2. Eighteen (18) to eighty-five (85) years of age&#xD;
&#xD;
          3. Body Mass Index (BMI) &lt; 40 (Wt. in Kgs / Ht. in m2)&#xD;
&#xD;
          4. Signed Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe cerebrovascular disease&#xD;
&#xD;
          2. Moderate to severe renal impairment (eGFR &lt; 30)&#xD;
&#xD;
          3. Active gastrointestinal bleeding&#xD;
&#xD;
          4. Active infection or fever&#xD;
&#xD;
          5. Short life expectancy&#xD;
&#xD;
          6. Significant anemia&#xD;
&#xD;
          7. Severe uncontrolled systemic hypertension&#xD;
&#xD;
          8. Severe electrolyte imbalance&#xD;
&#xD;
          9. Ejection fraction of &lt; 35%&#xD;
&#xD;
         10. Congestive heart failure (NYHA Class IV)&#xD;
&#xD;
         11. Unstable angina requiring emergent PTCA (percutaneous transluminal coronary&#xD;
             angioplasty) or CABG (coronary artery bypass graft)&#xD;
&#xD;
         12. Recent myocardial infarction&#xD;
&#xD;
         13. Bleeding or clotting disorders&#xD;
&#xD;
         14. Uncontrolled diabetes&#xD;
&#xD;
         15. Inability to receive IV or oral Anticoagulants&#xD;
&#xD;
         16. Unable to give informed consent (these patients would not be recruited)&#xD;
&#xD;
         17. Previous catheter or surgical ablation treatment for atrial fibrillation.&#xD;
&#xD;
         18. Paroxysmal atrial fibrillation.&#xD;
&#xD;
         19. Pregnancy (urinary pregnancy test will be offered on the day of the procedure for all&#xD;
             women of reproductive age)&#xD;
&#xD;
         20. Drug and/or alcohol abuse&#xD;
&#xD;
         21. Transient factors for AF&#xD;
&#xD;
         22. Severe LA enlargement of &gt;60 mm in diameter on echocardiography&#xD;
&#xD;
         23. Patients who have participated in another study of an investigational medicinal&#xD;
             product in the last 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phang B Lim, MB BChir</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College Healthcare NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Szabolcs Nagy, MD</last_name>
    <phone>447821694566</phone>
    <email>s.nagy@nhs.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Szabolcs Nagy, MD</last_name>
      <phone>447821694566</phone>
      <email>s.nagy@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 18, 2019</study_first_submitted>
  <study_first_submitted_qc>January 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2019</study_first_posted>
  <last_update_submitted>January 28, 2019</last_update_submitted>
  <last_update_submitted_qc>January 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiofrequency Catheter Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

